After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025'
March 19, 2025 10:08 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD)
The analyst comments "While recent reports (WSJ, Mar 18) suggest the Department of Health and Human Services may cut federal funding for HIV prevention, we believe... More
BTIG Reiterates Buy Rating on HealthEquity, Inc (HQY)
March 19, 2025 4:53 AM EDTBTIG analyst David Larsen reiterated a Buy rating and $130.00 price target on HealthEquity, Inc (NASDAQ: HQY).
The analyst comments "On Tuesday, 3/18/25 AMC, HQY reported F4Q:25 results. Total revenue of $311.8M +19% y/y was well ahead of BTIG / consensus estimates of $306.8M / $306M but adjusted EBITDA of $107.8M +9% y/y missed BTIG... More
